June 28, 2010Heart
Novel biochemical markers in suspected acute coronary syndrome: systematic review and critical appraisal
Why the study?
Do novel biochemical markers like IMA and H-FABP improve the early diagnosis of suspected acute coronary syndrome?
Population
Patients with suspected acute coronary syndrome (ACS) evaluated across 73 articles
Comparison
Early biochemical markers including CK-MB… vs Contemporary troponin assays (standard assessment)
Design
Systematic_review
Authors
Discussion
Loading...
Member takes
Implication
IMA/H-FABP may aid early ACS assessment; leaves open incremental value versus troponin pending rigorous comparative trials.
Structured PICO
Do novel biochemical markers like IMA and H-FABP improve the early diagnosis of suspected acute coronary syndrome?
P
Population
Patients with suspected acute coronary syndrome (ACS) evaluated across 73 articles
I
Intervention
Early biochemical markers including CK-MB, myoglobin, heart-type fatty acid binding protein (H-FABP), ischemia modified albumin (IMA), pregnancy-associated plasma protein A, glycogen phosphorylase isoenzyme BB, and myeloid-related protein 8/14
C
Comparator
Contemporary troponin assays (standard assessment)
O
Outcome
Diagnostic accuracy and clinical utility in the early assessment of ACSsurrogate
While IMA and H-FABP show promise for early ACS diagnosis, current evidence is limited by poor study design, highlighting the need for rigorous trials comparing them to contemporary troponin assays.
Limitations
- Many identified studies did not quantify clinical utility correctly
- Lack of adequately designed diagnostic studies against contemporary troponin assays
Cite This Study
Mosterd et al. (2010) studied this question.